From: Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment
Alteration | Occurrence (%) | References |
---|---|---|
PIK3CA mutations: | ||
Breast | 26% (1,559/6,110) | [108] |
Endometrium | 24% (282/1,194) | [108] |
Penis | 29% (8/28) | |
Urinary tract | 20% (189/942) | [108] |
Large intestine | 12% (779/6,710) | [108] |
Stomach | 12% (96/824) | [108] |
Ovary | 10% (163/1,590) | [108] |
Cervix | 10% (25/256) | [108] |
PIK3CA amplifications: | ||
Gastric | 67% to 36% | |
Papillary thyroid cancer | 53% (265/499) | [112] |
Head and neck | 55% to 37% | |
Non-small cell lung cancer | 31% | [115] |
Squamous cell carcinoma | 59% (31/52) | [116] |
Cervical | 70% to 44% | |
Ovarian | 35% (54/152) | [119] |
Prostate | 28% (9/32) | [120] |
Endometrial | 12% to 15% | |
Breast | 8% (8/92) | [123] |
Triple negative | 31% | [124] |
Chronic lymphocitic leukemia | 5% | [125] |
PIK3CB amplification: | ||
Breast | 5% | [72] |
Non-small cell lung cancer squamous cell carcinoma | 56% | [116] |
PTEN loss of heterozygosity: | ||
Glioblastoma | 59% | [126] |
Prostate | 15% to 70% | |
Breast | 11% to 38% | |
Melanoma | 33% (7/21) | [133] |
Gastric | 47% (14/30) | [111] |
Uveal melanoma | 76% to 39% | [134] |
PTEN mutation: | ||
Endometrium | 37% (690/1,860) | [135] |
Vulva | 62% (5/8) | [136] |
Central nervous system | 24% (491/2,055) | [137] |
Prostate | 14% (92/658) | [135] |
Melanoma | 16% (104/652) | [138] |
Uveal melanoma | 11% (4/35) | [134] |